ReviewStem cells translational medicine2025
Emerging clinical applications of ADAR based RNA editing.
Review in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities.Cellular & molecular biology letters · 2026Review
- A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.Nature biotechnology · 2026Article
- DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects.Molecular biomedicine · 2026Review
- Impact of mRNA and protein isoforms in lipoprotein metabolism and how to modulate them.Current opinion in lipidology · 2026Review
- The methyltransferase METTL16 in digestive system cancers: functions and mechanisms.Frontiers in oncology · 2026Review
- Regulatable In Vivo Gene Expression via Adaptamers.bioRxiv : the preprint server for biology · 2025Article
- TheInternational journal of molecular sciences · 2025Review
- Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management.Medical oncology (Northwood, London, England) · 2025Review
- Proteomic landscape of lung adenocarcinoma precancerous lesions reveals mitochondrial dsRNA-associated immune and stress responses.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
RNA editing via adenosine deaminases acting on RNA (ADARs) offers precise and reversible modifications at the RNA level, complementing traditional DNA-targeting therapies. ADAR enzymes catalyze the conversion of adenosine to inosine within double-stranded RNA, influencing critical cellular processes such as translation, splicing, and RNA stability. Utilizing endogenous ADARs guided by exogenous guide RNAs enables site-specific RNA editing without the need for transgenic editor expression, minimizing immunogenicity, and enhancing control over gene expression. Towards addressing the challenges in ensuring specificity, optimizing delivery methods, and navigating regulatory landscapes, ongoing innovations in guide RNA design, delivery technologies, and computational modeling are propelling the field forward. Already, initial clinical advancements are demonstrating the potential of ADAR-mediated RNA editing in treating human diseases. Collaborative efforts among researchers, clinicians, and industry partners are overcoming existing hurdles, progressively positioning ADAR-mediated RNA editing to revolutionize personalized medicine and provide effective treatments for a wide array of historically intractable diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.